spacer
home > ebr > winter 2019 > unlocking the power of data
PUBLICATIONS
European Biopharmaceutical Review

Unlocking the Power of Data

Communicating with tens or hundreds of collections individually on a global scale has been stated as one of the biggest bottlenecks in seeking data and samples for pharmaceutical research. Academic research groups and industry alike demand an ecosystem that facilitates the sharing of data in a secure environment.

A global trend of rapidly aging populations, combined with a declining birth rate, as well as a rising number of rare diseases without effective treatments, has created a pressing need for collaboration in the healthcare and research spaces to make advances that will help mitigate this shift (1). Additionally, genetic data production and integration into healthcare have exponentially increased with the rise of new technologies and consumer interest. Although these developments hold much promise, they pose significant challenges in dealing with the sheer volumes of data produced, as well as applying it to make conclusions that address some of the world’s largest current healthcare challenges. Thus, the urgency for more open data sharing across institutions is becoming apparent because scientists require access to unique datasets if they are to realise the promise that personalised healthcare may provide.

This opens the door for a global network that can guarantee a confidential and secure environment for biobanks to share their anonymised data with pharma researchers who seek suitable patient cohorts within validated data clouds on a global scale. Such a global ecosystem, presented in this article along with a description of the changing healthcare landscape, exists so that researchers can efficiently search for specific cohorts of patients for population research and rare tumours.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Timo Kanninen is Chief Architect and founder of BC Platforms and has been the visionary behind the company’s main products. He has a wealth of experience in software development, genetic epidemiology, statistical genetics, and clinical statistics. Previously, Timo was the founder, CEO, and Chief Technology Officer of Statwell Oy, which provided statistical consultation for the pharma industry and academic medical researchers and was merged into BC Platforms in 2002. He studied information technology in production and statistics at Helsinki University of Technology and Helsinki University, Finland, and has co-authored many articles in high level scientific journals.
spacer
Timo Kanninen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm Expands Relationship With Novan On Formulation Science

MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc. MedPharm has previously supported Novan by testing the company’s unique formulations using its proprietary in vitro models to optimise Novan’s formulations and de-risk product development.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement